NEW YORK, NY / ACCESSWIRE / April 19, 2017 / U.S. markets were dragged down by the Banking and Healthcare sectors Tuesday after Goldman Sachs and Johnson & Johnson reported earnings that fell short of expectations. The Dow Jones Industrial Average declined 0.55 percent to close at 20,523.28, while the S&P 500 Index fell 0.29 percent to close at 2,342.19.

"Earnings will be a key focus for investors over the next couple of weeks, but the number of geopolitical issues facing the market continues to grow," wrote Matt Maley, an equity strategist at Miller Tabak, in a note to clients Tuesday. "We're going to have to see a lot more upside follow through before we can say that the mild weakness we've seen since the beginning of March in the broad market has come to an end."

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Ltd.
https://ub.rdinvesting.com/news/?ticker=TEVA

Valeant Pharmaceuticals Intl Inc.
https://ub.rdinvesting.com/news/?ticker=VRX

Teva Pharmaceutical's shares declined 3.61 percent to close at $30.99 a share on Tuesday. The stock traded between $30.86 and $31.94 on volume of 9.61 million shares traded. On April 3rd, the company announced the approval of AUSTEDO (deutetrabenazine) the treatment of chorea associated with Huntington's disease (HD) from the U.S. Food and Drug Administration (FDA). The company is scheduled to release results for the first quarter of 2017 before market open in Thursday, May 11th. Shares of Teva Pharmaceutical have fallen approximately 14.51 percent year-to-date.

"Chorea associated with Huntington's disease has a significant impact on those living with the disease and their families," said Louise Vetter, Chief Executive Officer of the Huntington's Disease Society of America. "The FDA's approval of AUSTEDO? represents an important new treatment option for people with HD and highlights the need for more therapeutic resources for this underserved patient community."

Access RDI's Teva Pharmaceutical Research Report at:
https://ub.rdinvesting.com/news/?ticker=TEVA

Valeant Pharmaceuticals' shares dropped 5.59 percent to close at $8.95 a share on Tuesday. The stock traded between $8.92 and $9.42 on volume of 21.65 million shares traded. The company is scheduled to report results for the first quarter of 2017 on Tuesday, May 9th. Valeant's company annual meeting of shareholders for the year-ended December 31, 2016 is scheduled for Tuesday, May 2nd, 2017 at 9:00 a.m. ET. Shares of Valeant Pharmaceuticals have fallen approximately 38.36 percent year-to-date.

On April 6th, the company's wholly owned subsidiary, Bausch + Lomb, received 510(k) clearance from the FDA for the Stellaris Elite Vision Enhancement System, a next generation phacoemulsification cataract platform.

Access RDI's Valeant Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=VRX

Our Actionable Research on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com